Pharmacy Guide
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Pharmacy Guide
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Lamisil AT 1% Cream
⚠ This medicine appears to have been discontinued
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Terbinafine hydrochloride may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
What it is and what it is used for
FOR Lamisil AT 1% Cream contains the active ingredient terbinafine hydrochloride which is an antifungal used to treat fungal skin infections such as:
- Athlete's foot (tinea pedis) – Athlete's foot appears only on the feet (usually both, but not always), usually in between the toes. It can also appear on the instep, soles, or other areas of the feet. The most common type of athlete's foot causes cracking or scaling of the skin, but you may also have mild swelling, blisters, or weeping ulcers. Lamisil AT 1% Cream is recommended for athlete's foot when it occurs between the toes. If you have a fungal nail infection (fungus inside and under the nail) with discolouration of the nails and changes in nail texture (thick or flaky), you should consult your doctor because Lamisil AT 1% Cream is not appropriate for this type of infection.
- Dhobie itch/jock itch (tinea cruris) – Dhobie itch appears in the groin and inner thigh area, usually on both sides but often with one side more than the other, where it can spread further between the legs to the buttocks, or up towards the stomach. Dhobie itch looks like a clearly bordered rash, which may have blisters.
DO NOT use Lamisil AT 1% Cream if you:
- are allergic (hypersensitive) to any of the ingredients in the product (see Section 6). The cream is NOT recommended for use on children under 16 years of age. Take special care with Lamisil AT 1% cream The cream is for external use only. Do not use on the face. Avoid contact with the eyes. In case of accidental contact with eyes, rinse thoroughly with running water. Taking other medicines Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including those obtained without a prescription. Pregnancy and breast-feeding Do not use the cream if you are pregnant or breastfeeding, unless advised to by your doctor. Ask your doctor or pharmacist for advice before taking any medicine. Driving and using machines Lamisil AT 1% Cream is not expected to affect your ability to drive or operate machinery. Important information about some of the ingredients of Lamisil AT 1% Cream
- Lamisil AT 1% Cream contains 36 mg benzyl alcohol in each daily dosage which is equivalent to 10 mg/g. Benzyl alcohol may cause allergic reactions.
- Cetyl alcohol and stearyl alcohol: may cause local skin reactions (e.g. contact dermatitis).
How to take it
LAMISIL AT 1% CREAM Always use this medicine exactly as described in this leaflet or as advised by your doctor or pharmacist. Adults For athlete's foot and dhobie itch, apply the cream once a day, for one week.
- Cleanse and dry the affected areas thoroughly and wash your hands. Treatment can be helped by keeping the affected areas clean by regular washing and careful drying with your own clean towels and clothes, and not rubbing or scratching the skin.
- Unscrew the cap then gently squeeze out a small amount of the cream onto your finger.
- Apply just enough cream to form a thin layer on the affected skin and surrounding areas.
- Rub in gently. When used between the toes, buttocks or on the groin, the treated area may be covered with a light, fresh gauze strip, especially at night.
- Replace the cap on the tube and wash your hands. Even though you will not be using Lamisil AT 1% Cream during the second week, full skin healing after the 2003473_1/62000000208851
infection has cleared will continue for up to 4 weeks. If you have not noticed any signs of improvement within 2 weeks of first starting treatment, please seek advice from your doctor or pharmacist.
By reporting side effects you can help provide more information on the safety of this medicine.
Children under 16 years NOT recommended.
Keep out of the sight and reach of children. Keep the tube closed and in the carton. Do not use this medicine after the expiry (EXP) date shown on the box and tube. Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.
If you accidently swallow Lamisil AT 1% Cream Contact your doctor or nearest hospital emergency department if you, or someone else, has swallowed some cream. Take any remaining medicine and this leaflet with you if possible. Symptoms of accidental ingestion include headache, nausea (feeling sick), dizziness and stomach pain. If you forget to use Lamisil AT 1% Cream If you miss an application, apply the cream as soon as possible then continue your treatment as before. If you only remember at the time of your next application, just apply the cream and carry on as normal. It is important to try to use the cream at the correct times as forgotten applications could risk the infection returning. If you stop using Lamisil AT 1% Cream Infections may come back if you do not use the cream regularly, or if you stop the treatment too early. If you have any further questions on the use of this product, ask your doctor or pharmacist.
Possible side effects
Like all medicines, Lamisil AT 1% Cream can cause side effects, although not everybody gets them. STOP using the cream and seek medical help immediately if you have any of the following very rare allergic reactions:
- difficulty breathing or swallowing, swelling of the mouth, face, lips, tongue or throat (severe allergic reaction)
- severe itching of the skin, with a red rash or raised lumps, hives or blisters. Common (may affect up to 1 in 10 people): skin peeling, itching. Uncommon (may affect up to 1 in 100 people): skin lesions, scab, skin colour changes, redness, burning, pain and irritation at the site of application. These common and uncommon side effects are usually harmless and you can carry on using the cream. Rare (may affect up to 1 in 1000 people): eye irritation, dry skin, contact dermatitis, eczema, worsening of symptoms. Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
How to store it
LAMISIL AT 1% CREAM
6. FURTHER INFORMATION What Lamisil AT 1% Cream contains The active ingredient is terbinafine hydrochloride 1% w/w. The other ingredients are sodium hydroxide, benzyl alcohol, sorbitan stearate, cetyl palmitate, cetyl alcohol, stearyl alcohol, polysorbate 60, isopropyl myristate, purified water. (See also end of Section 2 for further information on some of the ingredients). What Lamisil AT 1% Cream looks like and contents of the pack The cream is available in aluminium or laminate tubes of 7 g, 7.5 g, 10 g or 15 g. Not all pack sizes may be marketed. Marketing Authorisation Holder: Karo Healthcare AB, Box 16184, 103 24 Stockholm, Sweden. Manufacturer: Karo Healthcare AB, Klara Norra Kyrkogata 33, 111 22 Stockholm, Sweden. This leaflet was last revised in December 2023.
2003473_1/62000000208851
Frequently asked questions about Lamisil AT 1% Cream
How do I take Lamisil AT 1% Cream?
Lamisil AT 1% Cream comes as cream. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
What is the active substance in Lamisil AT 1% Cream?
The active substance in Lamisil AT 1% Cream is terbinafine hydrochloride.
Are there equivalent medicines to Lamisil AT 1% Cream?
Medicines with the same active substance, strength and form include: Lamisil 1% w/w Cream, Terbinafine 1 % Cream. They are interchangeable only if your prescriber or pharmacist says so.
Where does this information come from?
This leaflet reproduces the patient information leaflet approved for Lamisil AT 1% Cream, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Can I get Lamisil AT 1% Cream without a prescription?
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
About this leaflet
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
- Source: electronic medicines compendium (emc), Datapharm
- Active substance: terbinafine hydrochloride
- Official document: view the original leaflet on emc →
⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
4.1. Therapeutic indications
The treatment of tinea pedis (athlete's foot) and tinea cruris (dhobie itch/jock itch) caused by Trichophyton (e.g. T. rubrum, T. mentagrophytes, T. verrucosum, T. violaceum) and Epidermophyton floccosum.
4.2. Posology and method of administration
Adults and children over 16 years of age
Lamisil AT 1% Cream is applied once daily.
Duration and frequency of treatment
Duration of treatment is one week for tinea pedis and tinea cruris. Relief of clinical symptoms usually occurs within a few days. Irregular use or premature discontinuation of treatment carries the risk of recurrence. If there are no signs of improvement after two weeks, the diagnosis should be verified by a physician.
Dosing in special populations:
Paediatric population
The experience with topical Lamisil AT 1% Cream in children is still limited and its use in children under 16 years cannot therefore be recommended.
Elderly patients
There is no evidence to suggest that elderly patients require different dosages or experience side-effects different to those of younger patients.
Method of administration
For cutaneous use.
The affected area should be cleaned and dried thoroughly before application of Lamisil AT 1% Cream. The cream should be applied to the affected skin and surrounding area in a thin layer and rubbed in lightly. In the case of intertriginous infections (interdigital, intergluteal, inguinal) the application may be covered with a gauze strip, especially at night.
4.3. Contraindications
Hypersensitivity to terbinafine or to any of the excipients contained in the cream, listed in section 6.1.
4.4. Special warnings and precautions for use
Lamisil AT 1% cream is for external use only.
Should be used with caution in patients with lesions where alcohol could be irritating.
Should not be used on the face.
Contact with the eyes should be avoided. May be irritating to the eyes. In case of accidental contact with the eyes, rinse the eyes thoroughly with running water.
Should be kept out of the sight and reach of children.
This medicine contains 36 mg benzyl alcohol in each daily dosage which is equivalent to 10 mg/g. Benzyl alcohol may cause allergic reactions.
Lamisil AT 1% Cream contains cetyl alcohol and stearyl alcohol which may cause local skin reactions (e.g. contact dermatitis).
4.5. Interaction with other medicinal products and other forms of interaction
There are no known drug interactions with Lamisil AT 1% Cream.
4.6. Fertility, pregnancy and lactation
Pregnancy
Foetal toxicity and fertility studies in animals suggest no adverse effects (see section 5.3).
There is no clinical experience with Lamisil AT 1% Cream in pregnant women. Lamisil AT 1% Cream should not be used during pregnancy, unless clearly necessay.
Lactation
Terbinafine is excreted in breast milk. Therefore mothers should not use Lamisil AT 1% Cream whilst breast-feeding.
Infants must not be allowed to come into contact with any treated skin, including the breast.
Fertility
No effects of terbinafine on fertility have been seen in animal studies (see section 5.3).
4.7. Effects on ability to drive and use machines
Lamisil AT 1% Cream has no influence on the ability to drive and use machines.
4.8. Undesirable effects
Local symptoms such as pruritis, skin exfoliation, application site pain, application site irritation, pigmentation disorder, skin burning sensation, erythema and scab may occur at the site of application.
These minor symptoms must be distinguished from hypersensitivity reactions such as widespread pruritis, rash, bullous eruptions and hives, which are reported in sporadic cases but require discontinuation.
In case of accidental contact with the eyes, terbinafine hydrochloride may be irritating to the eyes.
In rare cases the underlying fungal infection may be aggravated.
Adverse reactions are listed below by system organ class and frequency. Frequencies are defined as: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000), or not known (can not to be estimated from available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
Immune system disorders
Frequency not known: Hypersensitivity
Eye disorders
Rare: Eye irritation
Skin and subcutaneous tissue disorders
Common: Skin exfoliation, pruritus
Uncommon: Skin lesion, scab, skin disorder, pigmentation disorder, erythema, skin burning sensation
Rare: Dry skin, dermatitis contact, eczema
Frequency not known: Rash
General disorders and administration site conditions
Uncommon: Pain, application site pain, application site irritation
Rare: Condition aggravated
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.
4.9. Overdose
The low systemic absorption of topical terbinafine renders overdosage extremely unlikely.
Accidental ingestion of one 30g tube of Lamisil AT 1% Cream, which contains 300mg terbinafine hydrochloride is comparable to ingestion of one Lamisil 250mg tablet (adult oral unit dose).
Should a larger amount of Lamisil AT 1% Cream be inadvertantly ingested, adverse effects similar to those observed with an overdosage of Lamisil tablets are to be expected. These include headache, nausea, epigastric pain and dizziness.
If accidentally ingested, the recommended treatment of overdosage consists of eliminating the active substance, primarily by administration of activated charcoal and giving symptomatic therapy if needed.
💬 Ask about this leaflet
Ask anything about Lamisil AT 1% Cream. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.